---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006997"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:58.662354+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports preliminary Q4 2025 revenue $17.2M, VYD2311 Phase 3 trial initiated, top-line data mid-2026

## Summary
- Preliminary Q4 2025 PEMGARDA net product revenue of $17.2M, up 25% YoY from $13.8M and 31% QoQ from $13.1M.
- Ending 2025 cash and cash equivalents of $226.7M after raising over $200M in 2H 2025.
- Initiated DECLARATION Phase 3 pivotal trial of VYD2311 for COVID prevention; top-line data expected mid-2026.
- Fast Track designation for VYD2311 granted by FDA in December 2025.
- Selected potential best-in-class RSV antibody candidate VBY329; IND readiness targeted for 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-006997
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/0001193125-26-006997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/d93103d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006997
- JSON: https://secwatch.observer/filing/0001193125-26-006997.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.